CoreWeave's Order Book Is Full — It's the Balance Sheet That's Empty
Published on 10/24/2026 at 15:02 | Editorial boerse-global.de
CoreWeave's product engineers had a busy Wednesday. The company rolled out its Zero Trust AI Framework, a customer-controlled security model governing access to models, data and runtime environments, alongside Physical AI Launchables — pre-tested workload templates aimed at robotics, autonomous driving and simulation teams. Neither announcement says a word about how any of it gets paid for. That silence is precisely where the market's attention now sits.
The stock slipped 2.2% in the prior session, with Reuters attributing the pressure to CoreWeave's debt burden and the financing costs hanging over AI investment more broadly. Short sellers have done well out of that skepticism: Reuters reported that bearish positions in CoreWeave generated book gains of nearly $1.7 billion in October. Those are paper profits, not cash in hand, and they say nothing about the operating business — but they do measure how heavily investors have positioned against the shares.
Two Banks, One Diagnosis
UBS cut its price target to $105 from $120 on Monday while keeping a buy rating, and the reasoning is telling. Analyst Karl Keirstead still likes the demand picture, GPU pricing and the buildout of additional services. What worries him is leverage: heavy capital spending, negative free cash flow and debt leave CoreWeave exposed to higher interest rates. With roughly $129 billion in remaining contractual performance obligations on the books, UBS reckons the company will need about $20 billion in additional financing — and that rebuilding market confidence could take several quarters.
Morgan Stanley reached a similar conclusion from a different direction, trimming its target to $70 from $99 a day earlier. The bank explicitly credits CoreWeave's execution and its leading position in the neocloud sector; its concern is the funding bottleneck, not AI demand. Rising uncertainty, in its view, makes the pace of capacity expansion harder to plan. To fund its buildout through the end of 2027, Morgan Stanley estimates CoreWeave may need $24–37 billion in additional debt, with the quality of customer contracts shaping how lenders respond. Higher capital costs could slow the expansion — or force a capital raise that dilutes existing shareholders.
Should investors sell immediately? Or is it worth buying CoreWeave?
The two figures aren't directly comparable: UBS is sizing the financing of contracted demand, Morgan Stanley the capital required for a specific expansion path. Both point the same way, though. Strong demand does not by itself guarantee access to sufficient capital.
Backlog Is Not Bank Balance
That distinction matters because CoreWeave's order book, however impressive, is not cash already collected. Between signing a contract and booking revenue sit investments in the capacity needed to serve it — and it is exactly this upfront spending that has moved to the center of analyst attention. New customer agreements don't automatically ease the financial strain when fulfilling them requires further outlays first.
For shareholders, the takeaway is that growth potential and the ability to finance it are separate questions. A positive answer to the first does not resolve the second. UBS remains optimistic despite the lower target, but it isn't forecasting a quick restoration of confidence. The next meaningful milestone would be a financing arrangement that lets CoreWeave keep building without disproportionately burdening the investors who are already on board.
The product launches, meanwhile, describe what the company is building. The Reuters reports explain what is weighing on the shares — and it isn't the roadmap.
Ad
CoreWeave Stock: New Analysis - 24 October
Fresh CoreWeave information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
